Who are 18F-fluoromethylcholine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): F-18-Fluorocholine, Pluvicto, Pluvicto, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, Lu-177 PSMA-617, 177Lu-edotreotide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/18f-fluoromethylcholine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

18F-fluoromethylcholine — Competitive Intelligence Brief

18F-fluoromethylcholine (18F-fluoromethylcholine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioligand. Area: Oncology.

phase 2 Radioligand Choline kinase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

18F-fluoromethylcholine (18F-fluoromethylcholine) — Queen's Medical Center. PET imaging agent for prostate cancer

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
18F-fluoromethylcholine TARGET	18F-fluoromethylcholine	Queen's Medical Center	phase 2	Radioligand	Choline kinase
F-18-Fluorocholine	F-18-Fluorocholine	ABX advanced biochemical compounds GmbH	phase 3	PET imaging agent	Choline transporters; Choline kinase
Pluvicto	TETRAXETAN	Novartis	marketed	Radioligand Therapeutic Agent [EPC]		2025-01-01
Pluvicto	Lutetium (177Lu) vipivotide tetraxetan	Aaa Usa Novartis	marketed	Radioligand Therapeutic Agent [EPC]	Prostate-specific antigen	2022-01-01
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN		marketed	Radioligand Therapeutic Agent [EPC]	PSMA	2022-01-01
Lu-177 PSMA-617	Lu-177 PSMA-617	Radboud University Medical Center	phase 3	Radioligand therapy	PSMA (prostate-specific membrane antigen)
177Lu-edotreotide	177Lu-edotreotide	Grupo Espanol de Tumores Neuroendocrinos	phase 3	Radioligand therapeutic; somatostatin receptor agonist	Somatostatin receptor 2 (SSTR2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-08-15 — Pluvicto · 10406240 · US
2028-08-15 — Pluvicto · 11318121 · US
2034-10-17 — Pluvicto · 10398791 · US

Sponsor landscape (Radioligand class)

Clarity Pharmaceuticals Ltd · 1 drug in this class
GE Healthcare · 1 drug in this class
Queen's Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 18F-fluoromethylcholine — Competitive Intelligence Brief. https://druglandscape.com/ci/18f-fluoromethylcholine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab